Cargando…
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
AIMS: Atrial fibrillation (AF) is associated with higher mortality. Biomarkers may improve the understanding of key pathophysiologic processes in AF that lead to death. Using a new multiplex analytic technique, we explored the association between 268 biomarkers and cardiovascular (CV) death in antic...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302885/ https://www.ncbi.nlm.nih.gov/pubmed/34358298 http://dx.doi.org/10.1093/cvr/cvab262 |
_version_ | 1784751733697675264 |
---|---|
author | Pol, Tymon Hijazi, Ziad Lindbäck, Johan Oldgren, Jonas Alexander, John H Connolly, Stuart J Eikelboom, John W Ezekowitz, Michael D Granger, Christopher B Lopes, Renato D Yusuf, Salim Siegbahn, Agneta Wallentin, Lars |
author_facet | Pol, Tymon Hijazi, Ziad Lindbäck, Johan Oldgren, Jonas Alexander, John H Connolly, Stuart J Eikelboom, John W Ezekowitz, Michael D Granger, Christopher B Lopes, Renato D Yusuf, Salim Siegbahn, Agneta Wallentin, Lars |
author_sort | Pol, Tymon |
collection | PubMed |
description | AIMS: Atrial fibrillation (AF) is associated with higher mortality. Biomarkers may improve the understanding of key pathophysiologic processes in AF that lead to death. Using a new multiplex analytic technique, we explored the association between 268 biomarkers and cardiovascular (CV) death in anticoagulated patients with AF. METHODS AND RESULTS: A case–cohort design with 1.8- to 1.9-year follow-up. The identification cohort included 517 cases and 4057 randomly selected patients from ARISTOTLE. The validation cohort included 277 cases and 1042 randomly selected controls from RE-LY. Plasma collected at randomization was analysed with conventional immunoassays and the OLINK proximity extension assay panels: CVDII, CVDIII, and Inflammation. Association between biomarkers and CV death was evaluated using Random Survival Forest, Boruta, and adjusted Cox-regression analyses. The biomarkers most strongly and consistently associated with CV death were as follows (hazard ratio for inter-quartile comparison [95% CI]): N-terminal pro-B-type natriuretic peptide [NT-proBNP; 1.63 (1.37–1.93)], cardiac troponin T [cTnT-hs; 1.60 (1.35–1.88)], interleukin-6 [IL-6; 1.29 (1.13–1.47)], growth differentiation factor-15 [GDF-15; 1.30 (1.10–1.53)], fibroblast growth factor 23 [FGF-23; 1.21 (1.10–1.33)], urokinase receptor [uPAR; 1.38 (1.16–1.64)], trefoil factor 3 [TFF3; 1.27 (1.10–1.46)], tumour necrosis factor receptor 1 [TNFR1; 1.21 (1.01–1.45)], TNF-related apoptosis-inducing ligand receptor 2 [TRAILR2; 1.18 (1.04–1.34)], and cathepsin L1 [CTSL1; 1.22 (1.07–1.39)]. CONCLUSION: In this comprehensive screening of 268 biomarkers in anticoagulated patients with AF, the underlying mechanisms most strongly associated with CV death were cardiorenal dysfunction (NT-proBNP, cTnT-hs, CTSL1, TFF3), oxidative stress (GDF-15), inflammation (IL-6, GDF-15), calcium balance, vascular and renal dysfunction (FGF-23), fibrinolysis (suPAR), and apoptosis (TNFR1, TRAILR2). These findings provide novel insights into pathophysiologic aspects associated with CV death in AF. CLINICALTRIALS.GOV IDENTIFIER: NCT00412984 and NCT00262600. |
format | Online Article Text |
id | pubmed-9302885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-93028852022-07-22 Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation Pol, Tymon Hijazi, Ziad Lindbäck, Johan Oldgren, Jonas Alexander, John H Connolly, Stuart J Eikelboom, John W Ezekowitz, Michael D Granger, Christopher B Lopes, Renato D Yusuf, Salim Siegbahn, Agneta Wallentin, Lars Cardiovasc Res Original Article AIMS: Atrial fibrillation (AF) is associated with higher mortality. Biomarkers may improve the understanding of key pathophysiologic processes in AF that lead to death. Using a new multiplex analytic technique, we explored the association between 268 biomarkers and cardiovascular (CV) death in anticoagulated patients with AF. METHODS AND RESULTS: A case–cohort design with 1.8- to 1.9-year follow-up. The identification cohort included 517 cases and 4057 randomly selected patients from ARISTOTLE. The validation cohort included 277 cases and 1042 randomly selected controls from RE-LY. Plasma collected at randomization was analysed with conventional immunoassays and the OLINK proximity extension assay panels: CVDII, CVDIII, and Inflammation. Association between biomarkers and CV death was evaluated using Random Survival Forest, Boruta, and adjusted Cox-regression analyses. The biomarkers most strongly and consistently associated with CV death were as follows (hazard ratio for inter-quartile comparison [95% CI]): N-terminal pro-B-type natriuretic peptide [NT-proBNP; 1.63 (1.37–1.93)], cardiac troponin T [cTnT-hs; 1.60 (1.35–1.88)], interleukin-6 [IL-6; 1.29 (1.13–1.47)], growth differentiation factor-15 [GDF-15; 1.30 (1.10–1.53)], fibroblast growth factor 23 [FGF-23; 1.21 (1.10–1.33)], urokinase receptor [uPAR; 1.38 (1.16–1.64)], trefoil factor 3 [TFF3; 1.27 (1.10–1.46)], tumour necrosis factor receptor 1 [TNFR1; 1.21 (1.01–1.45)], TNF-related apoptosis-inducing ligand receptor 2 [TRAILR2; 1.18 (1.04–1.34)], and cathepsin L1 [CTSL1; 1.22 (1.07–1.39)]. CONCLUSION: In this comprehensive screening of 268 biomarkers in anticoagulated patients with AF, the underlying mechanisms most strongly associated with CV death were cardiorenal dysfunction (NT-proBNP, cTnT-hs, CTSL1, TFF3), oxidative stress (GDF-15), inflammation (IL-6, GDF-15), calcium balance, vascular and renal dysfunction (FGF-23), fibrinolysis (suPAR), and apoptosis (TNFR1, TRAILR2). These findings provide novel insights into pathophysiologic aspects associated with CV death in AF. CLINICALTRIALS.GOV IDENTIFIER: NCT00412984 and NCT00262600. Oxford University Press 2021-08-06 /pmc/articles/PMC9302885/ /pubmed/34358298 http://dx.doi.org/10.1093/cvr/cvab262 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Pol, Tymon Hijazi, Ziad Lindbäck, Johan Oldgren, Jonas Alexander, John H Connolly, Stuart J Eikelboom, John W Ezekowitz, Michael D Granger, Christopher B Lopes, Renato D Yusuf, Salim Siegbahn, Agneta Wallentin, Lars Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation |
title | Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation |
title_full | Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation |
title_fullStr | Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation |
title_full_unstemmed | Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation |
title_short | Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation |
title_sort | using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302885/ https://www.ncbi.nlm.nih.gov/pubmed/34358298 http://dx.doi.org/10.1093/cvr/cvab262 |
work_keys_str_mv | AT poltymon usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT hijaziziad usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT lindbackjohan usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT oldgrenjonas usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT alexanderjohnh usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT connollystuartj usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT eikelboomjohnw usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT ezekowitzmichaeld usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT grangerchristopherb usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT lopesrenatod usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT yusufsalim usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT siegbahnagneta usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation AT wallentinlars usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation |